Hangzhou Tigermed Sustainability Profile
Hangzhou Tigermed Consulting Co., Ltd., commonly known as Tigermed, is a leading clinical research organisation headquartered in Hangzhou, China. Founded in 2004, the company has established a strong presence across Asia, Europe, and North America, providing comprehensive services in the pharmaceutical and biotechnology sectors. Tigermed specialises in clinical trial management, regulatory affairs, and data management, offering unique solutions that streamline the drug development process. With a commitment to quality and innovation, the company has achieved significant milestones, including numerous successful trials for global clients. Recognised for its expertise and reliability, Tigermed holds a prominent position in the industry, contributing to advancements in healthcare and supporting the development of new therapies. Its dedication to excellence has earned it a reputation as a trusted partner in clinical research.
DitchCarbon Score
How does Hangzhou Tigermed's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Medical Device Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Hangzhou Tigermed's score of 39 is higher than 62% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Hangzhou Tigermed's reported carbon emissions
In 2024, Hangzhou Tigermed Consulting Co., Ltd. reported total carbon emissions of approximately 13,060,860 kg CO2e, comprising 116,820 kg CO2e from Scope 1 and 12,944,040 kg CO2e from Scope 2 emissions. This marks a slight decrease from 2023, where total emissions were about 13,850,210 kg CO2e, with Scope 1 at 118,730 kg CO2e and Scope 2 at 13,731,490 kg CO2e. The company has set ambitious reduction targets, aiming for a 15% decrease in both Scope 1 and Scope 2 emissions by 2025, relative to 2019 levels. Additionally, under the Science Based Targets initiative (SBTi), Tigermed has committed to reducing absolute Scope 1 and 2 emissions by 42% by 2030 from a 2023 baseline, and Scope 3 emissions by 25% within the same timeframe. These commitments reflect Tigermed's proactive approach to climate action within the pharmaceuticals, biotechnology, and life sciences sector, aligning with global efforts to mitigate climate change. The company has not disclosed any Scope 3 emissions data as of the latest reporting.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|
| Scope 1 | 63,180 | 00,000 | 00,000 | 00,000 | 00,000 | 000,000 | 000,000 | 000,000 |
| Scope 2 | 1,037,878 | 0,000,000 | 000,000 | 000,000 | 0,000,000 | 0,000,000 | 00,000,000 | 00,000,000 |
| Scope 3 | - | - | - | - | - | - | - | - |
How Carbon Intensive is Hangzhou Tigermed's Industry?
How Carbon Intensive is Hangzhou Tigermed's Location?
Hangzhou Tigermed's Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Hangzhou Tigermed has established climate goals through participation in recognized frameworks and target-setting initiatives. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
